Identifying Key Gene Signatures in Esophageal Cancer Therapy
Author Information
Author(s): Tian Kang, Yao Ziang, Pan Da
Primary Institution: The Affiliated Suqian Hospital of Xuzhou Medical University
Hypothesis
Can deubiquitination-related gene signatures predict outcomes in esophageal cancer patients?
Conclusion
The study identifies 14 deubiquitination-related genes that can predict patient outcomes and suggests MTOR as a potential therapeutic target for esophageal cancer.
Supporting Evidence
- The study developed a deubiquitination-related gene signature model based on 14 genes.
- Patients classified as high-risk had poorer survival rates and more genetic alterations.
- In vitro and in vivo experiments validated MTOR as a promising therapeutic target.
Takeaway
Researchers found that certain genes can help predict how well patients with esophageal cancer will do and that targeting a specific gene might help treat the disease better.
Methodology
The study used Cox regression models, single-cell RNA sequencing, and in vitro and in vivo experiments to analyze gene signatures.
Potential Biases
Potential biases may arise from the selection of datasets and the methodologies used for analysis.
Limitations
The study may not account for all variables affecting patient outcomes and relies on specific datasets.
Participant Demographics
The study involved esophageal cancer patients from TCGA and GEO datasets.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website